News and Press
Syntaxin Appoints Philip Boyd as Chief Financial Officer
News
MAR
2007
Syntaxin have appointed Philip Boyd as Chief Financial Officer. Philip joins Syntaxin from Evotec AG, where he was Senior Vice President, Finance and UK Finance Director.
Syntaxin welcome Philip Boyd as their new CFO
Syntaxin, Ltd, a biopharmaceutical company focusing on the discovery and development of novel drugs to control cell secretion, today announced the appointment of Philip Boyd as Chief Financial Officer. Philip joins Syntaxin from Evotec AG, where he was Senior Vice President, Finance and UK Finance Director.
A chartered management accountant, Philip has extensive financial and business experience from industry and consulting that is complemented by a scientific background. Prior to Evotec, Philip was Finance Director at Cambridge Discovery Chemistry, which was subsequently acquired by Millennium Pharmaceuticals Inc. Before this, he spent six years as a management consultant at PricewaterhouseCoopers, specialising in areas of operational and financial management across a wide range of industries, including pharmaceuticals. Philip received his BSc (Hons) degree in biotechnology and his PhD in genetics from University of Leeds, UK.
Patrick Doyle, CEO of Syntaxin commented: "I am delighted that Philip has joined our management team and look forward to working with him over the coming years. Philip brings a wealth of experience to the Company, and this will be invaluable to Syntaxin as we move forward and grow our business."
Philip Boyd said of his new appointment: "I am delighted to join Syntaxin at this exciting time. The Company's technology offers a great deal of promise in being able to offer new treatments for chronic conditions, and I am looking forward to playing my part in developing the business further."